Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Australia ‘undervalues’ the products of drug companies, Pfizer has told the Productivity Commission, echoing US lobbyists ...

These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...